Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Summary

The primary objective is to determine the maximum tolerated dose (MTD) of azacitidine and gemcitabine in subjects with previously untreated and unresectable pancreatic cancer. Also to determine the effect of azacitidine therapy on DNA methylation in peripheral blood cells.

Timeline

Start

2010-07

Primary completion

2014-01

Completion

2014-01

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated as the Prinicipal Investigator left the site- all previous subjects enrolled are deceased”

Drugs

Indications